IDEXX Laboratories (IDXX) · Life Sciences
IDEXX Laboratories Q3 2026 earnings: summary, key numbers & outlook
Results filed 2 Nov 2026 · Quarter ended 30 Sep 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
IDEXX placed over 1,900 inVue Dx analyzers in the quarter and bought AI clinical assistant CoVet, extending its diagnostics-plus-software push in veterinary practices.
IDEXX's growth this quarter was driven by volume, led by the inVue Dx analyzer, which had over 1,900 placements and brings the installed base to nearly 11,000 instruments. The premium instrument base grew 11% globally, and VetLab consumables use rose with new product launches. IDEXX Cancer Dx became a multi-cancer panel. International regions grew faster than the U.S., and imaging installations were strong, led by ImageVue DR50 Plus.
Management is pairing diagnostics with software, adding the CoVet AI clinical assistant to support veterinary team productivity and diagnostics utilization. Next up is the MultiCue Dx point-of-care analyzer, to be showcased at an investor session at VMX in January. The risks are integrating CoVet, acquisition costs that lowered the full-year operating margin outlook, and rapid assay volumes that are falling.
Key numbers
- Revenue · GAAP
- $1,214 million
- Diluted EPS · GAAP
- $4.01
- Net income · GAAP
- $317.1M
- Gross margin · GAAP
- 62.9%
- Operating income · GAAP
- $402.3M
- Operating margin · GAAP
- 33.1%
- Operating cash flow · GAAP
- $449.7M
- Free cash flow · non-GAAP
- $420.8M
an increase of 10% as reported and organic
an increase of 18% as reported and 22% on a comparable basis
increased 110 basis points as reported
up 13% as reported
higher by 100 basis points as reported
| Segment or metric | Value | Change |
|---|---|---|
| CAG Diagnostics recurring revenue | $967.4M | up 11% as reported and organic |
| IDEXX VetLab consumables | $443.2M | up 14% reported and 15% organic |
| Reference laboratory diagnostic and consulting services | $399.1M | up 10% reported and organic |
| Rapid assay products | $89.1M | up 1% as reported and organic |
| CAG Diagnostics capital instruments | $51.5M | flat |
| Veterinary software, services and diagnostic imaging systems | $97.1M | up 11% reported and 10% organic |
| Water | $58.8M | up 8% as reported and organic |
| Livestock, Poultry and Dairy | $34.8M | up 3% as reported and organic |
Where each number comes from
- Revenue: “The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group”
- Diluted EPS: “Third quarter earnings per diluted share (“EPS”) were $4.01, an increase of 18% as reported and 22% on a comparable basis.”
- Net income: “Net income attributable to stockholders | $317,145 | $274,610 | $934,003 | $811,276”
- Gross margin: “Gross margin of 62.9% increased 110 basis points as reported and 90 basis points on a comparable basis, supported by strong recurring revenue volume gains”
- Operating income: “Operating profit and growth (as reported) | $402,348 | $354,846 | 13% | $1,190,500 | $1,044,426 | 14%”
- Operating margin: “Operating margin was 33.1% for the quarter, higher than the prior year period by 100 basis points as reported and by 60 basis points on a comparable basis.”
- Operating cash flow: “Net cash provided by operating activities | $449,717 | $402,340 | $1,063,127 | $826,045”
- Free cash flow: “Free cash flow1 | $420,787 | $371,226 | $977,567 | $730,803”
- CAG Diagnostics recurring revenue: “CAG Diagnostics recurring revenue: | $967,351 | $873,273 | $94,078 | 10.8% | (0.2)% | — | 11.0%”
- IDEXX VetLab consumables: “IDEXX VetLab consumables | 443,245 | 387,813 | 55,432 | 14.3% | (0.3)% | — | 14.6%”
- Reference laboratory diagnostic and consulting services: “Reference laboratory diagnostic and consulting services | 399,079 | 362,725 | 36,354 | 10.0% | (0.2)% | — | 10.2%”
- Rapid assay products: “Rapid assay products | 89,135 | 88,638 | 497 | 0.6% | (0.2)% | — | 0.7%”
- CAG Diagnostics capital instruments: “CAG Diagnostics capital – instruments | $51,492 | $51,479 | $13 | — | (0.3)% | — | 0.4%”
- Veterinary software, services and diagnostic imaging systems: “Veterinary software, services and diagnostic imaging systems: | $97,125 | $87,782 | $9,343 | 10.6% | 0.1% | 0.7% | 9.9%”
- Water: “Water | $58,836 | $54,297 | $4,539 | 8.4% | 0.6% | — | 7.8%”
- Livestock, Poultry and Dairy: “LPD | $34,828 | $33,944 | $884 | 2.6% | (0.4)% | — | 3.0%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q3 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.2B | +9.9% | −0.2% |
| Operating income | $402.3M | +13.4% | −5.5% |
| Net income | $317.1M | +15.5% | −6.3% |
| Diluted EPS | $4.01 | +17.9% | −6.1% |
| Free cash flow | $420.8M | +13.4% | +30.5% |
| Gross margin | 62.9% | +1.1 pts | −1.1 pts |
| Operating margin | 33.1% | +1.0 pts | −1.9 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue | 2026 | $4,741 million - $4,767 million |
| Reported operating margin | 2026 | 32.1% - 32.3% |
| EPS | 2026 | $14.96 - $15.16 |
| Capital expenditures | 2026 | ~$160 |
Key takeaways
inVue Dx placements expand the premium installed base
IDEXX placed over 1,900 inVue Dx analyzers, bringing the installed base to nearly 11,000 instruments. Each placed instrument drives later consumables demand, so placements feed the recurring-revenue model.
CoVet acquisition adds AI to the software strategy
IDEXX acquired CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization. It links software workflow to testing demand, though integration is a named risk.
Cancer Dx becomes a multi-cancer panel
IDEXX Cancer Dx is now a multi-cancer panel, which IDEXX says helps practices detect disease earlier. It widens the use of reference-lab and in-clinic testing.
Volume, not price alone, drives consumables growth
VetLab consumables grew 14% reported, supported by an 11% larger premium installed base, utilization gains from new launches and net price gains. Rapid assay revenue grew only 1% as price offset lower testing volumes.
International diagnostics outgrows the U.S.
CAG Diagnostics recurring revenue grew 13% reported and 14% organic internationally against 10% in the U.S. IDEXX says both outpaced sector growth.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $954.3M * |
| Q1 2025 | $998.4M |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.1B |
| Q4 2025 | $1.1B * |
| Q1 2026 | $1.1B |
| Q2 2026 | $1.2B |
| Q3 2026 | $1.2B |
Data
| Q1 2025 | $2.96 |
| Q2 2025 | $3.63 |
| Q3 2025 | $3.40 |
| Q1 2026 | $3.47 |
| Q2 2026 | $4.27 |
| Q3 2026 | $4.01 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 27.4% |
| Q1 2025 | 31.7% |
| Q2 2025 | 33.6% |
| Q3 2025 | 32.1% |
| Q4 2025 | 28.9% |
| Q1 2026 | 31.8% |
| Q2 2026 | 35.0% |
| Q3 2026 | 33.1% |
Data
| Q4 2024 | $232.8M |
| Q1 2025 | $207.9M |
| Q2 2025 | $151.6M |
| Q3 2025 | $371.2M |
| Q4 2025 | $326.3M |
| Q1 2026 | $234.3M |
| Q2 2026 | $322.5M |
| Q3 2026 | $420.8M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What was the main product news at IDEXX this quarter?
IDEXX placed over 1,900 inVue Dx analyzers, taking the installed base to nearly 11,000, and expanded IDEXX Cancer Dx into a multi-cancer panel. It also acquired the CoVet AI clinical assistant.
What is CoVet and why did IDEXX buy it?
CoVet is an AI clinical assistant that supports veterinary team productivity and diagnostics utilization. IDEXX says it creates more value for customers.
Where is demand strongest?
CAG Diagnostics recurring revenue grew 13% reported internationally versus 10% in the U.S. Growth came from same-store volume, new customers, premium instrument installs and innovation benefits.
What are the weak spots in the business?
Rapid assay revenue rose only 1% as price gains offset lower testing volumes, and capital instrument revenue was flat. Livestock, Poultry and Dairy grew 3%.
What is coming next from IDEXX?
IDEXX will present its next point-of-care analyzer, IDEXX MultiCue Dx, at an investor session at VMX on January 18. It also faces CoVet integration, which it cites as a risk.
Documents
SEC filing
Call recording
Call recording on YouTube ↗. Official replay ↗.